New drug combo targets rare, tough kidney cancers
Disease control
Recruiting now
This study tests a combination of two drugs, pembrolizumab and enfortumab vedotin, for people with rare and aggressive kidney cancers (collecting duct carcinoma and renal medullary carcinoma). About 23 adults with advanced or metastatic disease will receive the treatment for seve…
Phase: PHASE2 • Sponsor: Giuseppe Procopio • Aim: Disease control
Last updated May 06, 2026 16:03 UTC